Author/Authors :
Nourmohammadi, Hassan Department of Internal Medicine Shahid Mostafa Khomeini Hospital, Ilam, Iran , Abdan, Zahra Clinical Research Development Center - Imam Reza Hospital - Kermanshah University of Medical Sciences, Kermanshah, Iran , Ramezanpour, Melina Medical Student at Medical School - Mazandaran University of Medical Sciences, Sari, Iran , Abdollahipour, Razieh Department of Pharmaceutics - Faculty of Pharmacy - School of Pharmacy - Kermanshah University of Medical Sciences, Kermanshah, Iran , Sarokhani, Diana Research Center for Environmental Determinants of Health - School of Public Health - Kermanshah University of Medical Sciences, Kermanshah, Iran , Fakhri, Moloud Traditional and Complementary Medicine Research Center - Addiction Institute - Mazandaran University of Medical Sciences, Sari, Iran , Hasanpour Dehkordi, Ali Social Determinants of Health Research Center - School of Allied Medical Sciences - Shahrekord University of Medical Sciences, Shahrekord, Iran
Abstract :
Introduction: Anemia is a common complication of chronic kidney disease (CKD) due
to the insufficient production of erythropoietin by the kidneys. The administration of
erythropoietin is one of the most common methods for the treatment of patients with anemia.
Objectives: This study aimed to investigate the effect of the administration of synthetic
erythropoietin on hemoglobin levels in dialysis patients using a systematic review and meta-
analysis.
Methods: In order to identify the related studies, the international databases of Web of
Science, PubMed, Scopus, and Embase were searched from 2015 to 2020 using standard and
valid keywords. The data were analyzed using STATA software (version 14), and a p-value of
less than 0.05 was considered statistically significant.
Results: In 12 reviewed articles with a sample size of 4060 individuals, the standard effect size
of the effect of synthetic erythropoietin on Hb in dialysis patients was reported as 2.08 (95%
CI: 1.53-2.63), which was statistically significant; however, erythropoietin biosimilars did not
show similar results.
Conclusion: The administration of erythropoietin to hemodialysis patients increases Hb
levels by more than 2 units.
Keywords :
Erythropoietin , Hemoglobin , Dialysis , Subcutaneous , Intravenous
